- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04580303
CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
A Phase 2 Multicenter, Open-label, Randomized, Parallel-group, Multiple-dose Study to Assess the Effectiveness, Safety and Satisfaction With Collagenase Clostridium Histolyticum Grid Technique Injections of Buttock or Thigh Cellulite With Laxity in Adult Females
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Coral Gables, Florida, United States, 33146
- Endo Clinical Trial Site #3
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Endo Clinical Trial Site #2
-
-
New York
-
New York, New York, United States, 10021
- Endo Clinical Trial Site #1
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have a body mass index of 18 to <29.9 kilograms/square meters
Have either both buttocks or both posterolateral thighs with:
- Score of 2 or 3 (mild or moderate cellulite) as reported by the investigator using the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS)
- Hexsel Cellulite Severity Scale (CSS) Subsection D "Grade of Laxity, Flaccidity, or Sagging Skin" score of 2 or 3 (moderate or severe) as determined by the investigator
- Have a negative pregnancy test or be of non-childbearing potential
- Be willing and able to cooperate with the requirements of the study
- Be willing to apply sunscreen to the treatment areas before each exposure to the sun for the duration of the study (from the Screening Visit through the Day 180/Early Termination Visit).
Exclusion Criteria:
- Has a history of hypersensitivity or allergy to collagenase or any other excipients of CCH.
- During Screening has a CR-PCSS score of less than 2 or greater than 3 for the area to be treated (buttocks or thighs) and/or has a Hexsel CSS Subsection D "Grade of Laxity, Flaccidity, or Sagging Skin" score of less than 2 or greater than 3 (severe) for the areas to be treated (buttocks or thighs).
- Has a coagulation disorder, which requires anticoagulant or antiplatelet medication during the study (except for ≤150 mg aspirin daily), or has taken anticoagulant or antiplatelet medication(s) within 14 days before injection of study treatment (except for ≤150 mg aspirin daily).
- Is a prisoner, an individual with impaired decision making capacity, employees (temporary, part-time, full-time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), or in the judgment of the investigator the participant is disadvantaged and vulnerable to coercion due to lack of education, or due to poor economic circumstances.
- Has received any collagenase treatments at any time prior to treatment in this study and/or has received EN3835 or CCH in a previous investigational study for cellulite.
- Is pregnant and/or is breast-feeding or plans to become pregnant and/or to breast-feed during the course of the study.
- Has a history of scarring due to keloids or abnormal wound healing.
- Has local (in areas to be treated) conditions (thrombosis, vascular disorder, active infection/inflammation, active cutaneous alteration, tattoo/mole) that restricts study participation
- Has history of drug or alcohol abuse within the 5 years prior to the Screening Visit.
Has evidence of clinically significant abnormalities, as judged by the investigator, in any of the following: physical examination findings, electrocardiogram (ECG), clinical laboratory values, or vital signs.
The sponsor's medical monitor will be required to review the results for confirmation of eligibility in the case of any of the following: abnormalities in electrocardiograms indicating corrected QT interval (QTc) prolongation of 470 milliseconds or greater; and clinical laboratory values of liver enzymes
- Has used or intends to use any of the local application/therapies/injections/procedures that restricts study participation.
- Has any other condition(s) that, in the investigator's opinion, might indicate the participant to be unsuitable for the study.
- For the subset of participants participating in the collection of ultrasound data, the following exclusions will apply: participants will be excluded who have: a history of a spinal laminectomy, a previous history or presence of vascular abnormalities (for example, deep vein thrombosis, thrombophlebitis), a healing fracture, an impaired sensation within, or near, the planned treatment area, or any implants within, or near, the planned treatment area.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Uniform 0.1-milliliters (mL) 1-Aliquot Grid Injection Technique (Buttock)
Dose per participant per treatment visit = up to 1.68 milligrams (mg) of CCH (0.84 mg in each treatment area)
|
Delivered via uniform grid injection techniques.
Other Names:
|
Active Comparator: Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttock)
Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
|
Delivered via uniform grid injection techniques.
Other Names:
|
Active Comparator: Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thigh)
Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
|
Delivered via uniform grid injection techniques.
Other Names:
|
Active Comparator: Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thigh)
Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
|
Delivered via uniform grid injection techniques.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of 1-Level Responders (+1 or Better Score) on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) for Either Buttock or Either Thigh
Time Frame: Day 180
|
I-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3).
One-level I-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the I-GAIS at the analysis visit for that treatment area.
The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.
|
Day 180
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of 1-Level Responders (+1 or Better Score) on the I-GAIS for Either Buttock or Either Thigh
Time Frame: Days 28, 56, 84, 112, and 140
|
I-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3).
One-level I-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the I-GAIS at the analysis visit for that treatment area.
The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.
|
Days 28, 56, 84, 112, and 140
|
Percentage of 1-Level Responders (+1 or Better Score) on the Subject Global Aesthetic Improvement Scale (S-GAIS) for Either Buttock or Either Thigh
Time Frame: Days 28, 56, 84, 112, 140, and 180
|
S-GAIS assessments were based on digital photographs, and were performed separately for each of 2 treatment areas.
S-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the participant ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3).
One-level S-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the S-GAIS at the analysis visit for that treatment area.
The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.
|
Days 28, 56, 84, 112, 140, and 180
|
Change From Baseline in Body-Q Appraisal of Cellulite Total Score
Time Frame: Baseline, Day 180
|
The Body-Q Appraisal of Cellulite is a subset of 11 questions from the Body-Q questionnaire developed to measure participant perceptions of weight loss and/or body contouring.
Total score is the sum of all 11 question scores.
The minimum possible total score is 11 and the maximum possible total score is 44.
Higher scores indicate the individual is less bothered by their cellulite.
|
Baseline, Day 180
|
Change From Baseline in Hexsel Cellulite Severity Scale (CSS) Subsection D Severity Score
Time Frame: Baseline, Days 28, 56, 84, 112,140, and 180
|
Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite using a 4-point scale from a low of 0 to high of 3: 0 (absence of laxity, flaccidity, or sagging skin), 1 (slight draped appearance), 2 (moderate draped appearance), and 3 (severe draped appearance).
The investigator or qualified designee used the Hexsel CSS Subsection D to assess the severity of dermal laxity in each buttock or each thigh independently.
A decrease from baseline indicated a better outcome.
|
Baseline, Days 28, 56, 84, 112,140, and 180
|
Percentage of Participants Positive for Anti-AUX-I and Anti-AUX-II Antibodies
Time Frame: Day 180
|
Blood samples were collected to assess anti-clostridial class I collagenase (AUX-I) and anti-Clostridial class II collagenase (AUX-II) antibody levels.
The percentage of participants who were positive for anti-AUX-I and anti-AUX-II antibodies are presented.
|
Day 180
|
Percentage of Participants Positive for Neutralizing Antibodies to AUX-I and AUX-II
Time Frame: Day 180
|
Blood samples were collected to assess neutralizing antibodies to AUX-I and AUX-II.
The percentage of participants who were positive for neutralizing antibodies to AUX-I and AUX-II are presented.
|
Day 180
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: David Hernandez, Endo Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EN3835-224
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laxity; Skin
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Merz North America, Inc.Ulthera, IncCompletedMild to Moderate Skin Laxity Under the Chin | Mild to Moderate Skin Laxity on NeckUnited States
-
Apsara Medical CorporationCompleted
-
Ulthera, IncCompletedSkin Laxity of the décolletéUnited States
-
Ulthera, IncUniversity of Texas Southwestern Medical CenterCompletedMild to Moderate Skin Laxity on Cheek | Mild to Moderate Skin Laxity on Upper Neck | Mild to Moderate Subcutaneous Fat on Cheek | Mild to Moderate Subcutaneous Fat on Upper Neck
-
Derming SRLCompletedFace Skin LaxityItaly
-
Nashville Centre for Laser and Facial SurgeryBausch HealthUnknownFacial Skin Laxity
-
Ulthera, IncCompletedFacial Skin LaxityUnited States
-
Endo PharmaceuticalsCompletedLaxity; Skin | Cellulite | Edematous Fibrosclerotic PanniculopathyUnited States
Clinical Trials on collagenase clostridium histolyticum
-
Stony Brook UniversityCompletedAdhesion of Flexor Tendon of HandUnited States
-
Endo PharmaceuticalsCompletedEdematous SkinUnited States
-
Zachary GerutAdvance Biofactures CorporationCompleted
-
Endo PharmaceuticalsCompleted
-
Advance Biofactures CorporationCompletedLeiomyoma | Fibroids, UterineUnited States
-
Endo PharmaceuticalsCompletedCellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Endo PharmaceuticalsCompletedCellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Endo PharmaceuticalsCompletedEdematous Fibrosclerotic PanniculopathyUnited States
-
University of MiamiEndo PharmaceuticalsRecruitingSexual Dysfunctions, Psychological | Genital Diseases, Male | Peyronie DiseaseUnited States
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseAustralia